{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,22]],"date-time":"2026-07-22T18:20:32Z","timestamp":1784744432804,"version":"3.55.0"},"reference-count":66,"publisher":"MDPI AG","issue":"8","license":[{"start":{"date-parts":[[2025,4,18]],"date-time":"2025-04-18T00:00:00Z","timestamp":1744934400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Healthcare"],"abstract":"<jats:p>Background: Agitation is a frequent and challenging symptom in schizophrenia and bipolar disorder, characterized by heightened motor activity, emotional distress, and potential aggression. This symptom is most observed during acute episodes, representing a significant burden on patients, caregivers, and healthcare systems. Agitation is a leading cause of emergency department visits and psychiatric hospitalizations, necessitating prompt and effective interventions to ensure safety and mitigate its far-reaching impact. Traditional treatments, including high-potency antipsychotics and benzodiazepines, remain first-line options but are associated with significant drawbacks such as sedation, extrapyramidal symptoms, tolerance, and limited applicability in certain patient populations, especially those with respiratory or cardiac depression and the elderly. Non-pharmacologic strategies like de-escalation techniques and environmental modifications are invaluable but may be impractical in acute care settings, as speed and efficiency are critical in emergent settings. These limitations, including the onset of extrapyramidal symptoms with high-dose antipsychotics and the development of tolerance with benzodiazepines, highlight gaps in care, including the need for faster-acting, safer, and more patient-friendly alternatives that reduce reliance on physical restraints and invasive interventions. Methods: This review explores the evolution of treatments for agitation, focusing on alternative and innovative approaches. To highlight these treatments, an extensive review of the literature was conducted utilizing PubMed, Google Scholar, Embase.com, and other search engines. Results: Key developments include sublingual dexmedetomidine, recently FDA-approved, which offers sedation without respiratory depression and a non-invasive administration route. Similarly, subcutaneous olanzapine provides a more convenient alternative to intramuscular injections, reducing injection-related complications. Other emerging treatments such as gabapentin, pregabalin, and ketamine show promise in addressing agitation in specific contexts, including comorbid conditions and treatment-resistant cases. A comparative analysis of these therapies highlights their mechanisms of action, clinical evidence, and practical challenges. Conclusions: Future directions emphasize intranasal delivery systems, novel pharmacologic agents, and potential roles for cannabinoids in managing agitation. These innovations aim to balance rapid symptom control with improved patient safety and experience. The set back with these emerging techniques is a lack of standardized dosing and protocols. They also face ethical concerns, including the chance of misuse or abuse, as well as regulatory barriers, as they lack FDA approval and their legality changes between states. This review underscores the clinical, practical, and ethical considerations in advancing care for agitated patients, paving the way for more effective and compassionate management strategies in psychiatric settings.<\/jats:p>","DOI":"10.3390\/healthcare13080932","type":"journal-article","created":{"date-parts":[[2025,4,18]],"date-time":"2025-04-18T06:23:56Z","timestamp":1744957436000},"page":"932","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Novel and Emerging Treatments for Agitation in Schizophrenia and Bipolar Disorder"],"prefix":"10.3390","volume":"13","author":[{"ORCID":"https:\/\/orcid.org\/0009-0004-0983-4762","authenticated-orcid":false,"given":"Sydney A.","family":"Mashaw","sequence":"first","affiliation":[{"name":"School of Medicine, Louisiana State University Health Sciences Center Shreveport, Shreveport, LA 71103, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3140-357X","authenticated-orcid":false,"given":"Ahmed I.","family":"Anwar","sequence":"additional","affiliation":[{"name":"Department of Psychology, Quinnipiac University, Hamden, CT 06518, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Judy N.","family":"Vu","sequence":"additional","affiliation":[{"name":"School of Medicine, Louisiana State University Health Sciences Center Shreveport, Shreveport, LA 71103, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Austin S.","family":"Thomassen","sequence":"additional","affiliation":[{"name":"School of Medicine, Louisiana State University Health Sciences Center Shreveport, Shreveport, LA 71103, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-6344-7036","authenticated-orcid":false,"given":"Maya L.","family":"Beesley","sequence":"additional","affiliation":[{"name":"College of Natural Sciences and Mathematics, University of Denver, 2199 S University Blvd, Denver, CO 80210, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-4545-4523","authenticated-orcid":false,"given":"Sahar","family":"Shekoohi","sequence":"additional","affiliation":[{"name":"Department of Anesthesiology, Louisiana State University Health Sciences Center Shreveport, Shreveport, LA 71103, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2464-0187","authenticated-orcid":false,"given":"Alan D.","family":"Kaye","sequence":"additional","affiliation":[{"name":"Department of Anesthesiology, Louisiana State University Health Sciences Center Shreveport, Shreveport, LA 71103, USA"},{"name":"Departments of Pharmacology, Toxicology, and Neurosciences, Louisiana State University Health Sciences Center Shreveport, Shreveport, LA 71103, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2025,4,18]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"165","DOI":"10.5811\/westjem.2015.12.28763","article-title":"Managing Agitation Associated with Schizophrenia and Bipolar Disorder in the Emergency Setting","volume":"17","author":"Zeller","year":"2016","journal-title":"West. J. Emerg. Med."},{"key":"ref_2","unstructured":"(2025, April 02). Diagnostic and Statistical Manual of Mental Disorders: Fifth Edition Text Revision DSM-5-TRTM. Available online: https:\/\/psychiatryonline.org\/doi\/book\/10.1176\/appi.books.9780890425787."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"86","DOI":"10.3109\/15622975.2015.1132007","article-title":"Assessment and management of agitation in psychiatry: Expert consensus","volume":"17","author":"Garriga","year":"2016","journal-title":"World J. Biol. Psychiatry"},{"key":"ref_4","doi-asserted-by":"crossref","unstructured":"Pompili, M., Ducci, G., Galluzzo, A., Rosso, G., Palumbo, C., and De Berardis, D. (2021). The Management of Psychomotor Agitation Associated with Schizophrenia or Bipolar Disorder: A Brief Review. Int. J. Environ. Res. Public. Health, 18.","DOI":"10.3390\/ijerph18084368"},{"key":"ref_5","doi-asserted-by":"crossref","unstructured":"Tucker, J., Whitehead, L., Palamara, P., Rosman, J.X., and Seaman, K. (2020). Recognition and management of agitation in acute mental health services: A qualitative evaluation of staff perceptions. BMC Nurs., 19.","DOI":"10.1186\/s12912-020-00495-x"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"661","DOI":"10.4088\/JCP.15m10271","article-title":"Benzodiazepine Use and Risk of Mortality Among Patients With Schizophrenia: A Retrospective Longitudinal Study","volume":"77","author":"Fontanella","year":"2016","journal-title":"J. Clin. Psychiatry"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1007\/s13670-021-00358-6","article-title":"Emergent and Non-Emergent Agitation in the Older Adult: Evaluation and Management","volume":"10","author":"Subramanian","year":"2021","journal-title":"Curr. Geriatr. Rep."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"17","DOI":"10.5811\/westjem.2011.9.6864","article-title":"Verbal De-escalation of the Agitated Patient: Consensus Statement of the American Association for Emergency Psychiatry Project BETA De-escalation Workgroup","volume":"13","author":"Richmond","year":"2012","journal-title":"West. J. Emerg. Med."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1016\/j.ajem.2005.02.050","article-title":"Emergency management of agitation in schizophrenia","volume":"23","author":"Marco","year":"2005","journal-title":"Am. J. Emerg. Med."},{"key":"ref_10","first-page":"e6152","article-title":"Treatment Options for Acute Agitation in Psychiatric Patients: Theoretical and Empirical Evidence","volume":"11","author":"Zareifopoulos","year":"2019","journal-title":"Cureus"},{"key":"ref_11","doi-asserted-by":"crossref","unstructured":"Sampogna, G., Della Rocca, B., Di Vincenzo, M., Catapano, P., Del Vecchio, V., Volpicelli, A., Martiadis, V., Signorelli, M.S., Ventriglio, A., and Fiorillo, A. (2024). Innovations and criticisms of the organization of mental health care in Italy. Int. Rev. Psychiatry, 1\u201310.","DOI":"10.1080\/09540261.2024.2391800"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1016\/j.annemergmed.2018.04.027","article-title":"Intramuscular Midazolam, Olanzapine, Ziprasidone, or Haloperidol for Treating Acute Agitation in the Emergency Department","volume":"72","author":"Klein","year":"2018","journal-title":"Ann. Emerg. Med."},{"key":"ref_13","first-page":"290","article-title":"Haloperidol decanoate: A depot antipsychotic","volume":"22","author":"Hemstrom","year":"1988","journal-title":"Drug Intell. Clin. Pharm."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"396","DOI":"10.2165\/00003088-198917060-00004","article-title":"Pharmacokinetics of haloperidol","volume":"17","author":"Froemming","year":"1989","journal-title":"Clin. Pharmacokinet."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"3172","DOI":"10.1158\/1078-0432.CCR-22-3971","article-title":"The DRD2 Antagonist Haloperidol Mediates Autophagy-Induced Ferroptosis to Increase Temozolomide Sensitivity by Promoting Endoplasmic Reticulum Stress in Glioblastoma","volume":"29","author":"Shi","year":"2023","journal-title":"Clin. Cancer Res. Off. J. Am. Assoc. Cancer Res."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1017\/S1461145704004262","article-title":"A randomized, controlled comparison of the efficacy and tolerability of low and high doses of haloperidol in the treatment of first-episode psychosis","volume":"7","author":"Oosthuizen","year":"2004","journal-title":"Int. J. Neuropsychopharmacol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1097\/SPC.0000000000000395","article-title":"Benzodiazepines for agitation in patients with delirium: Selecting the right patient, right time, and right indication","volume":"12","author":"Hui","year":"2018","journal-title":"Curr. Opin. Support. Palliat. Care"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"148S","DOI":"10.1002\/j.1875-9114.1996.tb03669.x","article-title":"Benzodiazepines in schizophrenia","volume":"16","author":"Stimmel","year":"1996","journal-title":"Pharmacotherapy"},{"key":"ref_19","first-page":"214","article-title":"Benzodiazepine Pharmacology and Central Nervous System\u2013Mediated Effects","volume":"13","author":"Griffin","year":"2013","journal-title":"Ochsner J."},{"key":"ref_20","first-page":"7","article-title":"Issues in the Clinical Use of Benzodiazepines: Potency, Withdrawal, and Rebound","volume":"65","author":"Chouinard","year":"2004","journal-title":"J. Clin. Psychiatry"},{"key":"ref_21","unstructured":"Gillies, D., Beck, A., McCloud, A., Rathbone, J., and Gillies, D. (2005). Benzodiazepines alone or in combination with antipsychotic drugs for acute psychosis. Cochrane Database Syst. Rev., CD003079."},{"key":"ref_22","doi-asserted-by":"crossref","unstructured":"Zaporowska-Stachowiak, I., Stachowiak-Szymczak, K., Oduah, M.-T., and Sopata, M. (2020). Haloperidol in palliative care: Indications and risks. Biomed. Pharmacother. Biomed. Pharmacother., 132.","DOI":"10.1016\/j.biopha.2020.110772"},{"key":"ref_23","first-page":"9","article-title":"The effects of benzodiazepines on cognition","volume":"66","author":"Stewart","year":"2005","journal-title":"J. Clin. Psychiatry"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/j.genhosppsych.2020.08.008","article-title":"Intravenous haloperidol: A systematic review of side effects and recommendations for clinical use","volume":"67","author":"Beach","year":"2020","journal-title":"Gen. Hosp. Psychiatry"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"293","DOI":"10.3949\/ccjm.91a.23061","article-title":"Reducing the risks when using benzodiazepines to treat insomnia: A public health approach","volume":"91","author":"Chaplin","year":"2024","journal-title":"Cleve. Clin. J. Med."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"g445","DOI":"10.1136\/bmj.g445","article-title":"Safety of benzodiazepines and opioids in very severe respiratory disease: National prospective study","volume":"348","author":"Ekstrom","year":"2014","journal-title":"BMJ"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"219","DOI":"10.2165\/00023210-200216040-00002","article-title":"Pharmacological treatment of psychotic agitation","volume":"16","author":"Currier","year":"2002","journal-title":"CNS Drugs"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1001\/jama.2022.0799","article-title":"Effect of Sublingual Dexmedetomidine vs Placebo on Acute Agitation Associated With Bipolar Disorder: A Randomized Clinical Trial","volume":"327","author":"Preskorn","year":"2022","journal-title":"JAMA"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"215","DOI":"10.9758\/cpn.2023.21.2.215","article-title":"Sublingual Dexmedetomidine for the Treatment of Agitation in Patients with Schizophrenia and Bipolar Disorder","volume":"21","author":"Smith","year":"2023","journal-title":"Clin. Psychopharmacol. Neurosci."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"22m14447","DOI":"10.4088\/JCP.22m14447","article-title":"Sublingual Dexmedetomidine for the Treatment of Acute Agitation in Adults With Schizophrenia or Schizoaffective Disorder: A Randomized Placebo-Controlled Trial","volume":"83","author":"Citrome","year":"2022","journal-title":"J. Clin. Psychiatry"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1097\/YIC.0000000000000040","article-title":"Pharmacokinetics of olanzapine long-acting injection: The clinical perspective","volume":"29","author":"Heres","year":"2014","journal-title":"Int. Clin. Psychopharmacol."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"774","DOI":"10.1016\/j.jpainsymman.2010.02.017","article-title":"Subcutaneous Olanzapine for Hyperactive or Mixed Delirium in Patients with Advanced Cancer: A Preliminary Study","volume":"40","author":"Elsayem","year":"2010","journal-title":"J. Pain Symptom Manag."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"1339","DOI":"10.1038\/s41380-021-01386-6","article-title":"Gabapentin and pregabalin in bipolar disorder, anxiety states, and insomnia: Systematic review, meta-analysis, and rationale","volume":"27","author":"Hong","year":"2022","journal-title":"Mol. Psychiatry"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1177\/0091217415589295","article-title":"Psychotic and depressive symptoms after gabapentin treatment","volume":"49","author":"Evrensel","year":"2015","journal-title":"Int. J. Psychiatry Med."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1111\/acem.13725","article-title":"Psychiatric Outcomes of Patients With Severe Agitation Following Administration of Prehospital Ketamine","volume":"26","author":"Lebin","year":"2019","journal-title":"Acad. Emerg. Med."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1017\/S1092852924001834","article-title":"Ketamine and Esketamine Use for Mood Disorders with Psychosis: A Systematic Review of Dissociative and Psychotic Symptoms","volume":"29","author":"Costa","year":"2024","journal-title":"CNS Spectr."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1007\/s40263-018-0519-3","article-title":"Antidepressant Efficacy and Tolerability of Ketamine and Esketamine: A Critical Review","volume":"32","author":"Molero","year":"2018","journal-title":"CNS Drugs"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1007\/s12264-016-0081-2","article-title":"Risks Associated with Misuse of Ketamine as a Rapid-Acting Antidepressant","volume":"32","author":"Zhu","year":"2016","journal-title":"Neurosci. Bull."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.1176\/appi.ajp.158.7.1149","article-title":"Double-Blind, Placebo-Controlled Comparison of Intramuscular Olanzapine and Intramuscular Haloperidol in the Treatment of Acute Agitation in Schizophrenia","volume":"158","author":"Wright","year":"2001","journal-title":"Am. J. Psychiatry"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1080\/13543784.2020.1727884","article-title":"The treatment of acute agitation associated with schizophrenia or bipolar disorder: Investigational drugs in early stages of their clinical development, and their clinical context and potential place in therapy","volume":"29","author":"Ward","year":"2020","journal-title":"Expert Opin. Investig. Drugs"},{"key":"ref_41","doi-asserted-by":"crossref","unstructured":"Fortuna, A., Schindowski, K., and Sonvico, F. (2022). Editorial: Intranasal Drug Delivery: Challenges and Opportunities. Front. Pharmacol., 13.","DOI":"10.3389\/fphar.2022.868986"},{"key":"ref_42","doi-asserted-by":"crossref","unstructured":"Ladel, S., Flamm, J., Zadeh, A.S., Filzwieser, D., Walter, J.-C., Schlossbauer, P., Kinscherf, R., Lischka, K., Luksch, H., and Schindowski, K. (2018). Allogenic Fc Domain-Facilitated Uptake of IgG in Nasal Lamina Propria: Friend or Foe for Intranasal CNS Delivery?. Pharmaceutics, 10.","DOI":"10.3390\/pharmaceutics10030107"},{"key":"ref_43","unstructured":"(2025, January 03). Selective CNS Targeting and Distribution with a Refined Region-Specific Intranasal Delivery Technique via the Olfactory Mucosa-PubMed, Available online: https:\/\/pubmed.ncbi.nlm.nih.gov\/34834319\/."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"884","DOI":"10.1021\/mp100029t","article-title":"Trigeminal pathways deliver a low molecular weight drug from the nose to the brain and orofacial structures","volume":"7","author":"Johnson","year":"2010","journal-title":"Mol. Pharm."},{"key":"ref_45","doi-asserted-by":"crossref","unstructured":"Achar, A., Myers, R., and Ghosh, C. (2021). Drug Delivery Challenges in Brain Disorders across the Blood\u2013Brain Barrier: Novel Methods and Future Considerations for Improved Therapy. Biomedicines, 9.","DOI":"10.3390\/biomedicines9121834"},{"key":"ref_46","unstructured":"(2025, January 03). Intranasal Route\u2014An overview|ScienceDirect Topics. Available online: https:\/\/www.sciencedirect.com\/topics\/pharmacology-toxicology-and-pharmaceutical-science\/intranasal-route."},{"key":"ref_47","doi-asserted-by":"crossref","unstructured":"Kisku, A., Nishad, A., Agrawal, S., Paliwal, R., Datusalia, A.K., Gupta, G., Singh, S.K., Dua, K., and Sulakhiya, K. (2024). Recent developments in intranasal drug delivery of nanomedicines for the treatment of neuropsychiatric disorders. Front. Med., 11.","DOI":"10.3389\/fmed.2024.1463976"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"105812","DOI":"10.1016\/j.ejps.2021.105812","article-title":"Impact of gastrointestinal tract variability on oral drug absorption and pharmacokinetics: An UNGAP review","volume":"162","author":"Vinarov","year":"2021","journal-title":"Eur. J. Pharm. Sci."},{"key":"ref_49","first-page":"1","article-title":"Intranasal Emergency Drug Delivery: A Review","volume":"1","author":"Abdallah","year":"2024","journal-title":"Endocrinol. Diabetes Open Access J."},{"key":"ref_50","unstructured":"(2025, January 03). Alternative Approaches for Addressing Acute Agitation in Schizophrenia and Bipolar Disorder. Available online: https:\/\/www.psychiatrist.com\/pcc\/alternative-approaches-addressing-acute-agitation-schizophrenia-bipolar-disorder\/."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1186\/s12967-024-04908-2","article-title":"Intranasal delivery of mitochondria targeted neuroprotective compounds for traumatic brain injury: Screening based on pharmacological and physiological properties","volume":"22","author":"Pandya","year":"2024","journal-title":"J. Transl. Med."},{"key":"ref_52","unstructured":"(2025, January 03). Neurelis\u00ae Pipeline: About NRL-4 for Acute Agitation Episodes. Available online: https:\/\/www.neurelis.com\/our-pipeline\/nrl-1004\/."},{"key":"ref_53","unstructured":"Impel Pharmaceuticals (2025, January 03). A Phase 2a, Randomized, Double-Blind, Placebo-Controlled, Single Dose, 2-Way, 2-Period Crossover Safety and Exploratory Efficacy Study of INP105 (POD-OLZ) for the Acute Treatment of Agitation in Adolescents and Young Adults with Autism Spectrum Disorder; Report No.: NCT05163717, Available online: https:\/\/clinicaltrials.gov\/study\/NCT05163717."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"19m13086","DOI":"10.4088\/JCP.19m13086","article-title":"The SNAP 101 Double-Blind, Placebo\/Active-Controlled, Safety, Pharmacokinetic, and Pharmacodynamic Study of INP105 (Nasal Olanzapine) in Healthy Adults","volume":"81","author":"Shrewsbury","year":"2020","journal-title":"J. Clin. Psychiatry"},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"2045125319881916","DOI":"10.1177\/2045125319881916","article-title":"Cannabidiol as a potential treatment for psychosis","volume":"9","author":"Davies","year":"2019","journal-title":"Ther. Adv. Psychopharmacol."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1007\/s13311-015-0387-1","article-title":"Cannabidiol as a Potential Treatment for Anxiety Disorders","volume":"12","author":"Blessing","year":"2015","journal-title":"Neurotherapeutics"},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"5131","DOI":"10.2174\/138161212802884681","article-title":"A Critical Review of the Antipsychotic Effects of Cannabidiol: 30 Years of a Translational Investigation","volume":"18","author":"Zuardi","year":"2012","journal-title":"Curr. Pharm. Des."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"137723","DOI":"10.1016\/j.neulet.2024.137723","article-title":"Cannabidiol exhibits anxiolytic-like effects and antipsychotic-like effects in mice models","volume":"826","author":"Shu","year":"2024","journal-title":"Neurosci. Lett."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"1253","DOI":"10.1016\/j.jagp.2021.01.015","article-title":"Cannabinoids for Agitation in Alzheimer\u2019s Disease","volume":"29","author":"Outen","year":"2021","journal-title":"Am. J. Geriatr. Psychiatry Off. J. Am. Assoc. Geriatr. Psychiatry"},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"1","DOI":"10.5498\/wjp.v12.i1.1","article-title":"Prevalence and correlates of aggressive behavior in psychiatric inpatient populations","volume":"12","author":"Girasek","year":"2022","journal-title":"World J. Psychiatry"},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1080\/15504263.2016.1245457","article-title":"The Effects of Cannabis on Inpatient Agitation, Aggression, and Length of Stay","volume":"12","author":"Johnson","year":"2016","journal-title":"J. Dual Diagn."},{"key":"ref_62","unstructured":"(2025, January 03). Farm Bill|Home, Available online: https:\/\/www.usda.gov\/farming-and-ranching\/farm-bill."},{"key":"ref_63","unstructured":"(2025, April 02). Cannabidiol (CBD)\u2013Potential Harms, Side Effects, and Unknowns, Available online: https:\/\/library.samhsa.gov\/product\/advisory-cannabidiol-cbd-potential-harm-side-effects-and-unknowns\/pep22-06-04-003."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1093\/jncimonographs\/lgab009","article-title":"Challenges for Clinical Cannabis and Cannabinoid Research in the United States","volume":"2021","author":"Cooper","year":"2021","journal-title":"J. Natl. Cancer Inst. Monogr."},{"key":"ref_65","doi-asserted-by":"crossref","unstructured":"Roberts, J., Gracia Canales, A., Blanthorn-Hazell, S., Craciun Boldeanu, A., and Judge, D. (2018). Characterizing the experience of agitation in patients with bipolar disorder and schizophrenia. BMC Psychiatry, 18.","DOI":"10.1186\/s12888-018-1673-3"},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"107631","DOI":"10.1016\/j.neuropharm.2019.05.008","article-title":"Men and women respond differently to antipsychotic drugs","volume":"163","author":"Seeman","year":"2020","journal-title":"Neuropharmacology"}],"container-title":["Healthcare"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2227-9032\/13\/8\/932\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T17:17:12Z","timestamp":1760030232000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2227-9032\/13\/8\/932"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,18]]},"references-count":66,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2025,4]]}},"alternative-id":["healthcare13080932"],"URL":"https:\/\/doi.org\/10.3390\/healthcare13080932","relation":{},"ISSN":["2227-9032"],"issn-type":[{"value":"2227-9032","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4,18]]}}}